Tuttle KR, Bosch-Traberg H, Cherney DZI, Hadjadj S, et al. Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared to placebo. Kidney Int 2023 Feb 2:S0085-2538(23)00056-X. doi: 10.1016/j.kint.2022.
PMID: 36738891